协和医学杂志

2020, v.11(05) 626-630

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

免疫检查点抑制剂在复发/转移性鼻咽癌中的应用
Application of Immune-checkpoint Inhibitors in Recurrent/Metastatic Nasopharyngeal Carcinoma

高洋;孙昭;白春梅;
GAO Yang;SUN Zhao;BAI Chun-mei;Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College;

摘要(Abstract):

鼻咽癌多与EB病毒感染相关,早期患者及时治疗后预后良好,但复发/转移性鼻咽癌治疗方式有限,预后不佳。近年来,免疫治疗在复发/转移性鼻咽癌中的研究十分广泛,其中免疫检查点抑制剂药物具有较好的疗效和良好的耐受性,引起临床广泛关注。程序性死亡受体-配体1(programmed death-ligand 1, PD-L1)表达状态、肿瘤突变负荷、循环EB病毒-DNA水平可能成为免疫检查点抑制剂疗效预测的生物标志物。本文将对免疫检查点抑制剂及其在复发/转移性鼻咽癌中的应用进行综述。
Nasopharyngeal carcinoma is mainly associated with Epstein-Barr virus(EBV) infection. The treatment of early nasopharyngeal carcinoma has a good prognosis, but the treatment options for recurrent/metastatic nasopharyngeal carcinoma are limited and the prognosis is poor. In recent years, there have been extensive studies on immunotherapy in advanced nasopharyngeal carcinoma, among which immune-checkpoint inhibitors are effective and causing clinical concern. Programmed death-ligand 1 expression status, tumor mutation burden and circulating EBV-DNA level may be biomarkers for predicting the efficacy of immune-checkpoint inhibitors. The applications of immune-checkpoint inhibitors in recurrent/metastatic nasopharyngeal carcinoma will be reviewed in this article.

关键词(KeyWords): 鼻咽癌;免疫检查点抑制剂;生物标志物
nasopharyngeal carcinoma;immune-checkpoint inhibitor;biomarker

Abstract:

Keywords:

基金项目(Foundation): 中国医学科学院医学与健康科技创新工程(2016-12M-1-001)

作者(Author): 高洋;孙昭;白春梅;
GAO Yang;SUN Zhao;BAI Chun-mei;Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享